Development and validation of a prognostic model for HER2-low breast cancer to evaluate neoadjuvant therapy

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC) accounts for 30–51% of all BCs. How to precisely assess the response to neoadjuvant therapy in this heterogenous tumor is currently unanswered. With the advance in multi-omics, refining the molecular subtyping other t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoping, Lin, Zhiquan, Yu, Qihe, Qiu, Chaoran, Lai, Chan, Huang, Hui, Zhang, Yiwen, Zhang, Weibin, Zhu, Jintao, Huang, Xin, Li, Weiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005989/
https://www.ncbi.nlm.nih.gov/pubmed/36915818
http://dx.doi.org/10.21037/gs-22-729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005989/
https://www.ncbi.nlm.nih.gov/pubmed/36915818
http://dx.doi.org/10.21037/gs-22-729

Ejemplares similares